Compare Johnson & Johnson (JNJ) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Johnson & Johnson trades at $260.85 (market cap $618.09B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.67 (market cap $7.77B). The key difference: Johnson & Johnson is far larger — about 79.5× Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF pays none. Which is the better fit depends on your goals.
| JNJ | PDBC | |
|---|---|---|
Market Cap | $618.09B | $7.77B |
Volume | 6,050,983 | 6,100,303 |
Sector | Health | — |
52-Week High | $278.43 | $20.10 |
52-Week Low | $186.00 | $13.16 |
Typical Hold Time | 129 Days | — |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
PDBC (Invesco Optimum Yield Diversified Commodity Strategy ETF) trades at $19.68, up 1.39% with strong bullish momentum. The ETF has delivered exceptional performance, rising 45.66% year-to-date driven by energy and agricultural gains amid geopolitical turmoil. Technical indicators show bullish moving averages but neutral oscillators, with RSI at 72.89 suggesting potential overbought conditions. Recent institutional activity shows significant position increases despite a 215% surge in short interest.
The outlook remains positive given strong commodity trends and defensive positioning appeal, though elevated short interest and geopolitical risks warrant caution. Commodity exposure provides inflation hedge benefits, but price volatility and concentrated sector risks require careful monitoring for investors seeking diversified commodity exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
